THE MCMANUS GROUP for ROCHE DIAGNOSTICS
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Access to and reimbursement of medical devices, specifically diagnostics, in the Medicare program. Issues related to Medicare reimbursement for clinical laboratory services under the Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) of 2014. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing a transitional coverage period, including H.R. 5343/S. 1717- Ensuring Patient Access to Critical Breakthrough Products Act of 2025.
Foreign entity interest: 100% ownership by F. Hoffman-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, SUI
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAWREN D GEER | — |
| JOHN MCMANUS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.